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Hereditary etiologies of pancreatic and hepatobiliary cancers are increasingly recognized. An estimated >10% of pancreatic and
increasing number of hepatobiliary cancers are hereditary. The cumulative risk of hereditary pancreatic cancer ranges from
measurable but negligible in cystic ﬁbrosis to a sobering 70% in cases of hereditary pancreatitis. Candidates for pancreatic cancer
surveillancearethosewithariskpancreaticcancerestimatedtobe>10-foldthatofthenormalpopulation.Screeningforpancreatic
cancerinhigh-riskindividualsistypicallyperformedbyendoscopicultrasoundandshouldbeginatleast10yearspriortotheageof
the youngest aﬀected relative. Disease states known to be associated with increased risk of hepatocellular cancer include hereditary
hemochromatosis,autoimmunehepatitis,porphyria,andα1-antitrypsindeﬁciency,withrelativerisksashighas36-fold.Although
much less is known about hereditary bile-duct cancers, Muir-Torre syndrome and bile salt export pump deﬁciency are diseases
whose association with hereditary carcinogenesis is under investigation.
1.Introduction
Hereditary etiologies of carcinogenesis have been increas-
ingly recognized over the past century. In 1889, Billroth was
one of the ﬁrst to recognize the occurrence of multiple
primary malignant neoplasms [1] and Lynch et al. in 1967
one of the ﬁrst to draw attention to the etiologic role of
hereditary factors in their occurrence [2]. Since then, at least
78 identiﬁed genetic syndromes of hereditary cancer have
been described [3] and many more syndromes undoubtedly
remain to be identiﬁed.
Recent molecular and genetic advancements have
brought international attention to pancreatic cancer (PC),
withanestimated>10%ofcasesbeinghereditaryinetiology.
Although less common then hereditary PC, hereditary
hepatobiliary cancers are also increasingly recognized.
2. PancreasCancer
PC is a lethal disease, with 277,000 new cases diagnosed per
year globally [4]; in the USA, it was estimated to be 43,140
new cases of pancreatic cancer and 36,800 deaths from the
disease in 2010 [5]. The deﬁnition of familial, or hereditary
PC (HPC), the vast majority of which is pancreatic ductal
adenocarcinoma (PDAC), is generally accepted to be deﬁned
as PC occurring in families with ≥2 ﬁrst-degree relatives
(FDRs) [6].
Six years after the landmark 1967 publication by Lynch
et al. on the role of hereditary factors in the occurrence of
multipleprimarymalignantneoplasms[2],akindredoffour
siblings with pancreas adenocarcinoma was described [7].
Over the next two decades, several more publications high-
lighted the importance of the hereditary form of pancreatic
adenocarcinoma,notonlywithinasinglegenerationbutalso
across multiple generations and families [8, 9]( Table 1).
Population-based case-control studies have quantiﬁed
the increase in risk for individuals from families with con-
vincing family histories of PDAC. For example, a study in
1990 from the Hereditary Cancer Institute at Creighton
University identiﬁed familial clustering among 47 cases of
pancreatic cancer in 18 nuclear families with two or more
ﬁrst-degree relatives aﬀected [10]. In this study, while only
0.7% of controls had positive family histories of the disease,
6.7% of PDAC cases had positive family histories. Ghadirian
et al. [11] conducted a similar study on 179 French-speaking
patients in Montr´ eal and found that 7.8% of the patients2 International Journal of Surgical Oncology
Table 1: Epidemiological studies of HPC.
Study,
year [ref] Type Location No. of patients Findings
Falk,
1988 [9] Case control Louisiana, USA 363 OR 5.25 if FH
Lynch,
1990 [10] Descriptive Nebraska, USA 47 10-fold increased occurrence of PC if FH of
PC (7.8% versus 0.6%)
Ghadirian,
1991 [11] Case control Montr´ eal, Canada 179 13-fold increased occurrence of PC if FH of
PC (6.7% versus 0.7%)
Fernandez,
1994 [12] Case control Italy 362 4-fold increased occurrence of PC if FH of
PC (3.9% versus 1.1%); RR 3 if FH
Dergham,
1997 [13] C a s es e r i e s D e t r o i t ,U S A 8 1 9 %o c c u r r e n c eo fP Ci fF Ho fP C .
Coughlin,
2000 [14] Cohort USA 3751 RR 1.5 (men)–1.7 (women) if FH
Hemminki,
2003 [15] Cohort Sweden 21,000 SIR 2.4 if FH (parent)
Klein,
2004 [16] Registry Baltimore, USA 5179 S I R3 2i f3F D Rw i t hP C S I R6 . 4i f2F D R
with PCSIR 4.5 if 1 FDR with PC
Permuth-
Wey,
2008 [17]
Meta-analysis USA, Italy,
Canada, Japan 6568 RR 3.4 if FH of PC
OR: odds ratio; RR: relative risk; SIR: standardized incidence ratio; FH: family history; FDR: ﬁrst-degree relative.
who had PDAC had a family history of the disease compared
with only 0.6% of the control population representing a 13-
fold increase. Dergham et al. [13] reported a similar ﬁgure of
9% of pancreatic cancer patients having a family history. In
a Northern Italy study including >300 patients with PDAC,
a family history of pancreatic cancer was associated with an
increased relative risk of 3 for the development of pancreatic
cancer (RR = 3) [12].
Larger, national studies [14, 15] and a meta-analysis of
studies [17] of thousands to tens of thousands of patients
with PC similarly have revealed an increased relative risk
ranging from 1.5 to 3.4 based on family history of PC. The
risk of PC in family members of those who have PC is likely
best estimated by analysis of the National Familial Pancreas
TumorRegistryatJohnsHopkins Hospital[16]:among5179
individuals in 838 kindreds, the risk (standardized incidence
ratios) of persons with 1, 2, or 3 FDRs with PC was 4.6, 6.4,
and 32, respectively (Table 1).
In addition to familial PC, among other genetic defect(s)
which remain to be discovered, there are at least ﬁve well-
described inherited proﬁles with known genetic defects that
substantiallyincreasethecarrier’scumulativelifetimeriskfor
developing HPC (Table 2).
2.1. Speciﬁc Diseases with Inherited Predisposition for
Pancreatic Cancer
2.1.1. Hereditary Pancreatitis. Hereditary pancreatitis (HP)
isanautosomaldominantdiseasethatpresentswithepisodes
of acute pancreatitis in early childhood, as early as 5 years of
age. As a result of such early onset of acute pancreatitis, most
of these patients develop chronic pancreatitis in their second
decade of life, unlike chronic alcoholic pancreatitis which
presents later in life. Chronic HP is further distinguished
from chronic alcoholic pancreatitis by the equal gender ratio,
but is otherwise largely similar to nonhereditary pancreatitis
(Table 3)[ 34].
Any diﬃculty diﬀerentiating HP from the nonhereditary
form on the basis of biochemical and laboratory diﬀerences
was mitigated by the discovery of a genetic diﬀerence: a 1996
study of ﬁve kindreds with hereditary pancreatitis revealed
that an arginine-histamine substitution at residue 117 of the
cationic trypsinogen gene, PRSS1, was associated with the
phenotypic expression of acute pancreatitis due to failure
of the aﬀected trypsinogen, leading to autodigestion of the
pancreas [35]. A second mutation was later described—a
single A to T mutation—to be associated with a less severe
form of hereditary pancreatitis [36].
Hereditary pancreatitis is associated with a markedly in-
creased risk (53-fold) for developing PC (Table 2), which
usually develops after several decades of pancreatitis espe-
cially in those with paternal mode of inheritance [18].
Smoking, a known risk factor for PC, was found to have
an even more pronounced detrimental eﬀect on those with
hereditary pancreatitis: in a cohort of 497 patients, smoking
wasfoundtodouble therisk forPCand tobeassociated with
a 2-decade-earlier onset of PC compared with nonsmoking
status [37].
2.1.2. Familial Atypical Multiple Mole Melanoma Syndrome.
The familial atypical multiple mole melanoma syndrome
(FAMMM) is an autosomal dominant syndrome associated
with an increased risk of cutaneous melanoma, dysplastic
nevi, and PC, among other neoplasms. The association of
the FAMMM syndrome with PC was described in 1990
by Bergman et al. [21], who studied nine families (200
individuals) with FAMMM in the Netherlands, reportingInternational Journal of Surgical Oncology 3
Table 2: Known inherited syndromes associated with increased risk of HPC.
Syndrome Genes Gene function Rate of PC in
syndrome O/E → risk of PC Cumulative risk of PC References
HP PRSS1;
SPINK1
Trypsinogen;
Protease Inhibitor
8/246 = 3.2%
10/200 = 5.0%
26/418 = 6.2%
8/0.15 → 53
10/0.115 → 87
26/NR → 67
25–70% [18–20]
FAMMM CDKN2/P16 Tumor suppressor
9/200 = 4.5%
66/466 = 14%
15/656 = 2.3%
6/0.16 → 38a
2/0.03 → 65b
8/0.6 → 13
13–17% [21–23]
HBOC
BRCA1;
BRCA2;
(PALB2)
Tumor suppressor 14/1181 = 1.2% 14/4.4 → 5.9
7/1.3 → 8.9c 1.2–6.9% [24–26]
PJ STK11/LKB1 Tumor suppressor 6/240 = 2.5%
4/31 = 13% NR/NR → 132 5–36% [27–29]
HNPCC
MLH1;
MSH2;
MSH6;
PMS2
DNA mismatch
repair 47 cases in 31 families O/E→ 8.6 3.7% [30]
CF CFTR
Transmembrane
conductance
regulator
1/28, 842 = 0.0035%d 1/0.4 → 2.6
7/1.7 → 5.3 “Negligible” [31, 32]
FPC Unk. Unk.
2/1253 = 0.16%
4/634 = 0.63%
5/106 = 4.7%
2/0.44 → 4.5
4/0.62 → 6.4
5/0.16 → 32
NR [33]
NR: not reported; HP: hereditary pancreatitis; FAMMM: familial atypical multiple mole melanoma; HBOC: hereditary breast and ovarian cancer; PJ: Peutz-
Jeghers; HNPCC: hereditary nonpolyposis colorectal cancer; FPC: familial pancreas cancer; CF: cystic ﬁbrosis.
aFemales ≥56 years old.
bFemales <55 years old.
cIf outside the ovarian cancer cluster region.
dA total of nine patients have subsequently been identiﬁed by Maisonneuve et al. [31, 32].
Families, not individuals.
Table 3: Comparison of chronic alcoholic and chronic hereditary pancreatitis.
Pancreatitis type Chronic alcoholic pancreatitis Chronic hereditary pancreatitis P
Male to female ratio 12.5:1 1:1
Age of onset (years) 40 10.5 <.05
Delay in diagnosis (years) 3 14.3 <.05
Presence of pseudocysts 10% 33% <.05
Presence of pancreatic calciﬁcations 57% 58% NS
Endocrine insuﬃciency 70% 50% NS
Exocrine insuﬃciency 42% 38% NS
Need for surgery 41% 50% NS
Modiﬁed from [34].
nine cases of PC, which has a 13.4-fold increased risk
compared with the general population.
The CDKN2A gene, also known as P16,i sat u m o r - s u p -
pressor gene with various mutations implicated in the devel-
opmentofFAMMMaswellasothersystemiccancers.Studies
of FAMMM individuals whose P16/CDKN2A was rendered
dysfunctional by mutations have noted that the risk of PC
was increased 15- to 38-fold [22, 38].
2.1.3. Hereditary Breast and Ovarian Cancer Syndrome and
PALB2 Loss. Mutations of BRCA1 and BRCA2, common in
hereditary breast and ovarian cancer (HBOC) syndrome,
predispose carriers to developing breast, ovarian, and a vari-
ety of other cancers including PC. Sequencing of BRCA2 in
individuals with HPC from North American [39]a n dE u r o -
pean[40]HPCregistrieshaverevealeddeleteriousmutations
in nearly one-ﬁfth of these individuals, making BRCA2 the
most common genetic defect in HPC. Loss of BRCA2 in
HPC has been observed to confer an increased risk of PC
as high as nearly 9-fold [24]. The role of BRCA1 seems
to be less pronounced, but still measureable at a 2- to 3-
fold increased risk of PC in carriers of BRCA1 mutations
[25, 26]. Goggins et al. at Johns Hopkins University [41]
studied 41 unselected adenocarcinomas of the pancreas, 15
of which had allelic loss at the BRCA2 locus and 4 of those4 International Journal of Surgical Oncology
(9.8% overall) had a second-allele abnormality. Three of
these four cancers (7.3% overall) were considered germ-line
mutations (with conﬁrmation in normal tissue) suggesting
that the rate of germ-line BRCA2 mutations in apparently
sporadic pancreatic cancer may be as high as in breast or
ovarian cancer [41].
The recently recognized partner and localizer of BRCA2,
PALB2, is also frequently lost in HPC, at a rate of approx-
imately 3% in recent North American [42]a n dE u r o p e a n
[43] sequencing studies of HPC kindreds, making it the
secondmostcommonlylostgeneinHPC.Knowledgeofsuch
mutations as BRCA2 and PALB2 has major therapeutic
implications; PC in this group of patients has been shown
to be exquisitely sensitive to DNA cross-linking agents such
as mitomycin C (MMC) [44].
2.1.4. Peutz-Jeghers Syndrome. Peutz-Jeghers syndrome
(PJS) is an autosomal dominant syndrome associated with
loss of STK11/LKB1 gene function and is characterized by
hamartomatous polyps in the gastrointestinal tract and
pigmented skin lesions on the lips, oral mucosa, and digits.
In a large retrospective cohort study of 34 PJS patients
identiﬁed over 50 years of Mayo Clinic records, the overall
risk for developing cancer in aﬀected individuals was 9.9.
The relative risk of developing gastrointestinal cancers was
50.5, and the risk was 5-fold higher in women (RR 151)
than men (RR 30) [45]. The risk for developing PC was
reported to be 5% at the age of 40 and 8% at the age of 60
in a study of 240 international PJS patients possessing the
STK11 mutation [27]. Of note, all pancreatic cancers in that
study were diagnosed between the age of 34 and 49 years
[27]. That multi-institutional eﬀort was recently extended to
include 419 PJS patients, 297 with an identiﬁed STK11/LKB1
germ-line mutation [46], with similar results in the risk of
PC (3- and 7-fold risk at 40 and 60 years of age, respectively.
2.1.5. Lynch Syndrome. Lynch syndrome, also known as he-
reditary nonpolyposis colorectal cancer (HNPCC), is an au-
tosomal dominant condition associated with mutations in
DNA mismatch repair (MMR) genes including MLH1,
MSH2, MSH6, PMS2, and others. The resulting compromise
of DNA maintenance and repair leads to the accumulation of
errors in the genome manifested in microsatellite instability
and loss of normal tumor-suppressor function. Whereas
Lynch I syndrome is comprised only of colorectal cancers,
Lynch II has been characterized to include a number of
extracolonic cancers including PC.
Kastrinos et al. [30] analyzed the data on 6,342 individ-
uals from 147 families with MMR gene mutations from two
majorUScancercentersandfoundthat21.1%ofthefamilies
reported a case of pancreatic cancer. The cumulative risk of
pancreatic cancer in these individuals was 1.3% at age 50 and
3.7% at age 70, which corresponds to a an 8.6-fold increase
compared to the general population [30].
2.2.SurveillanceandScreeningforPC. PC,speciﬁcallyPDAC,
is generally a lethal disease, and even at high-volume insti-
tutions, the median survival following resection of PDAC
is less than 20 months and the 5-year survival is only 20%
[47]. However, when very small, very favorable cases of PC
are selected, long-term survival is possible, with 4- and 5-
year survivals of 78% and 59% reported [48, 49]. Usually,
such cases are incidentally and fortuitously discovered at an
early stage. While screening the low-risk general population
for PC would be associated with an unfavorable risk/beneﬁt
ratio (due the low overall incidence of PC and to the lack of
a screening test that is readily available, noninvasive, and
accurate), screening a population at very high (>10-fold
[50]) risk may oﬀer an opportunity to cure an otherwise un-
curable cancer if discovered early.
Investigators at the University of Washington were
among the ﬁrst to describe the use of prospective screening
and surveillance for high-risk individuals [51]: 7 of 14
individualsfrom3high-riskfamilieswhowerescreenedwith
endoscopic ultrasonography (EUS), endoscopic retrograde
cholangiopancreatography (ERCP), computed tomography
(CT), and serum CEA and CA19-9 were found to have high-
risk lesions based on concerning features on EUS and ERCP
features. Pancreatectomy was therefore recommended and
performed in all 7 patients, and all 7 patients had widespread
dysplasia (PanINs), but no cancer or normal pancreas
parenchyma was found in any of the specimens [51]. In
a follow-up study at the same institution, Kimmey et al.
screened46high-riskpatientswithEUS[52]:13patientshad
abnormal ﬁndings, 12 of whom underwent pancreatectomy
withall12specimensshowingwidespreaddysplasia(PanIN).
Canto et al. [53] at Johns Hopkins similarly reported on
38 high-risk (most with ≥3 relatives with PC) individuals
who underwent screening with EUS and, if abnormal,
then biopsy, ERCP, and CT. Resection was oﬀered to and
performed on 6 patients with a mass seen on EUS. On ﬁnal
pathology, 4 patients had a benign lesion, one patient had
an IPMN, and one patient had PDAC [53]. Other centers
around the world, including Germany, the Netherlands, and
the US [54–56] have similarly begun screening programs.
Recommendations regarding screening and surveillance
are in evolution. The University of Washington currently
recommends surveillance to the following: (1) individuals
with 2 or more ﬁrst-degree relatives with PC, (2) individuals
with one ﬁrst-degree relative with PC diagnosed under
the age of 50, (3) individuals with 2 or more relatives
with pancreatic cancer, one of whom had PC at an early
age, and (4) individuals with a genetic disorders, such as
PJS and FAMMM [57]. Screening recommendations of the
Fourth International Symposium of Inherited Diseases of
the Pancreas [50], including both University of Washington
and Johns Hopkins investigators, are slightly more stringent
(Table 4) and include anyone deemed to have a risk of PC
≥10-fold the general population. As such, candidates for
screening and surveillance include those with FAMMM, PJS,
HP, or ≥3 ﬁrst-degree relatives with PC, individuals with
≥3 ﬁrst-, second-, or third-degree relatives with PC (at least
one of whom is a ﬁrst-degree relative), any member of a
PJS family, those carrying mutations of BRCA1, BRCA2,o r
an MMR gene, and with at least one ﬁrst- or second-degree
relative with PC, and candidates with 2 relatives with PC inInternational Journal of Surgical Oncology 5
Table 4: Candidates for pancreatic cancer surveillance.
Candidates for PC surveillance (with >10-fold increased risk of PC)
Anyone with ≥3 ﬁrst-degree relatives with PC
Individuals with ≥3 ﬁrst-, second-, or third-degree relatives with PC, at least one of whom is a ﬁrst-degree relative
Anyone with FAMMM, PJS, or HP
Any member of a PJS family
Carriers of mutations of BRCA1, BRCA2, or an MMR gene and with at least one ﬁrst- or second-degree relative with PC
A person with 2 relatives in the same lineage (directly connected) with PC, at least one of whom is a ﬁrst-degree relative of the candidate
Some people with two ﬁrst-degree relatives with PC and favorable expert opinion
Modiﬁed from [50].
the same lineage (directly connected), at least one of whom
is a ﬁrst-degree relative of the candidate [50].
After deciding which patients to screen, the questions of
how and when to screen remain. In addition to EUS and
ERCP, magnetic resonance imaging with cholangiopancre-
atography(MRI/MRCP)hasmorerecentlygainedincreasing
interest as a screening modality. Vasen et al. [58] used
MRI/MRCP to screen high-risk individuals with P16-leiden
mutations. After a 4-year median follow-up period, out of
79 individuals screened, pancreatic cancer was diagnosed in
9% and precursor lesions in 11% [58]. Whichever screening
tool is employed, a screening program should take place
only in the setting of a high-volume center and with full
informed consent. Patients who are not willing to undergo
pancreatectomyforsuspiciouslesionsidentiﬁedonscreening
should not undergo screening. Care must also be taken to
exclude patients with a recent history of pancreatitis or
heavy alcohol intake, since EUS ﬁndings are similar in that
population [59].
Normal EUS ﬁndings include homogenous parenchyma
and a thin-walled, anechoic main pancreatic duct. Abnormal
EUS features that are considered to warrant ERCP followup
(Figure 1) include hypoechoic nodules and cysts, echogenic
foci, parenchymal heterogeneity, narrowing or dilation of
the pancreatic duct, and duct-wall echogenicity [52, 53, 59–
61]. Unfortunately, many of these changes are also present
in chronic pancreatitis and in recent heavy alcohol intake,
as such patients must be stratiﬁed accordingly. Concerning
ERCP features include saccular deformities or other irregu-
larities of the pancreatic ducts [60, 61].
When to start screening is similarly not universally
deﬁned [50]. Applying the screening principles of colorectal
cancer by beginning screening for pancreatic cancer 10 years
earlier than the youngest aﬀected member in the family is
a reasonable starting point. Taking into account, however,
the long time between initiation of a PDAC tumor cell and
the presence of a PDAC tumor beginning to have metastatic
capability (11.7 ± 3.1 years [62]), and taking into account
evidence that consecutive generations with FPC die of PC
a median of 10 years sooner each subsequent generation
[63], and ﬁnally taking into account that smokers with FPC
develop cancer a decade before nonsmokers, it is reasonable
to use judgment in screening selected individuals much
earlier. A reasonable screening algorithm is presented in
Figure 1.
≥10x risk, ≥10years earlier
than earliest aﬀected relative
Pancreas-protocol CT or MRI/MRCP
CEA, Ca19-9, liver and pancreas labs,
genetic testing?
Recent alcohol No recent alcohol
Abstain ≥1month EUS
Abnormal Normal
Repeat EUS 1–3y ERCP
Normal Abnormal
Consider resection
Figure 1: Flow chart for pancreatic cancer screening in high-risk
individuals.
The treatment of patients who are deemed to have high-
r i s kf o rc a n c e ro rap r e c a n c e rl e s i o na n dw h oa r ef o u n dt o
have an abnormality by screening is pancreatectomy. Some
recommend routine total pancretectomy, citing multifocality
of the disease [59], whereas others recommended partial
pancreatectomy [53]. Inadequate data exist to determine
which option is associated with the most favorable risk/
beneﬁt ratio, but each patient’s ability to manage the severe
diabetes following total pancreatectomy must be weighed
carefully on a case-by-case basis with the risk of leaving
behind at-risk pancreas.
3.HepatobiliaryCancers
3.1. Hepatocellular Carcinoma. Compared with PC, much
less is known about hereditary hepatobiliary cancers. Al-
though the great majority of hepatocellular carcinoma
(HCC) cases are sporadic, some data exist to suggest6 International Journal of Surgical Oncology
Table 5: Inherited diseases of the liver associated with HCC.
Inherited diseases of the liver associated with HCC
Disease RR References
Hereditary hemochromatosis 2–20 [66–68]
Autoimmune hepatitis 23 [69]
Porphyria 5–36 [70, 71]
α1-antitrypsin deﬁciency 5 [72]
Progressive familial intrahepatic cholestasis Unk. [73, 74]
Glycogen storage disease type 1
(von Gierke disease) Unk. [75]
Hereditary tyrosinemia type I Unk. [76–78]
Wilson’s disease Unk. [79]
Niemann-Pick disease Unk. [80]
Gaucher disease Unk [81]
Hereditary telangiectasias Unk. [82, 83]
an inherited component of risk. In a study of nearly 5000
HBV carriers from the Liver Unit of Chang-Gung Memorial
Hospital and the Government Employee Central Clinics in
Taipei, those who had a family history of HCC had a 2.4-
fold risk of HCC compared with HBV carriers without
a family history of HCC and this risk increased to 5.6-
fold if two or more relatives were aﬀected [64]. Similarly,
analysis of the Swedish Cancer Registry [65], covering >10
millionindividuals,revealeda4.7-foldincreasedriskofHCC
in oﬀspring of patients with HCC. In addition to general
familial risk, several speciﬁc, known inherited liver diseases
have been associated with increased risk for the development
of HCC (Table 5).
3.1.1. Speciﬁc Diseases with Inherited Predisposition for HCC.
Hereditaryhemochromatosis(HH)isanautosomalrecessive
disease associated with various mutations in the HFE gene
resulting in progressive iron overload in the liver and else-
where and is associated with an increased risk of HCC. To
study whether HH, per se, and not chronic liver disease, is
responsible for the increased cancer risk, Fracanzani et al.
[66] analyzed the rate HCC in 230 patients with HH and
230otherswithnoniron-relatedchronicliverdisease,ﬁnding
a 1.9-fold increased risk of HCC in HH patients after
controlling for alcohol abuse, smoking, and family history
of cancer. In a modeling study using published life tables,
age-speciﬁc cancer rates, and DNA studies of archived liver
biopsy specimens, Haddow et al. [67] calculated the lifetime
risk of HCC in a cohort of 5000 men with the common
homozygous C282Y mutation in the HFE gene to be 23-
fold compared with 1,000,000 normal men. Elmberg et al.
[68] studied 1847 Swedish patients with HH and 5973 of
their ﬁrst-degree relatives. Patients with HH had a 20-fold
increased risk of HCC, but their ﬁrst-degree relatives had
no increased risk of overall cancers and an only 1.5-fold
increased risk of hepatobiliary cancers such as HCC [68].
A recent meta-analysis of 9 studies including 1102 HCC
cases and 3766 controls in Europe revealed that the C282Y
mutation but not the H63D mutation was associated with
HCC in patients with alcoholic cirrhosis [84].
Other hereditary liver diseases have been associated with
increased risk of HCC development, such as autoimmune
hepatitis (RR 23) [69], porphyria (RR 5–36) [70, 71],
α1-antitrypsin deﬁciency (RR 5) [72], progressive familial
intrahepatic cholestasis (RR 3.7) [73, 74], glycogen storage
diseasetype1(vonGierkedisease)(RRunk.)[75],hereditary
tyrosinemia type I (RR unk.) [76–78], Wilson’s disease (RR
unk.) [79], Niemann-Pick disease (RR unk.) [80], Gaucher
disease (RR unk.) [81], and hereditary telangieatasias (RR
unk.) [82, 83], but these associations are poorly studied due
to the rarity of the disease processes.
3.2. Bile-Duct and Gallbladder Cancer. I nal a r g e ,c o o p e r a -
tive, case-control series from Milan, Fernandez et al. [12]
prospectively followed 740 patients with pancreatic and
hepatobiliary cancers compared with 1408 matched control
patients and found a family history of gallbladder cancer in
1 of 58 patients with gallbladder cancer and in 2 of 1408
controls, yielding a relative risk of 13.9 but with a wide
conﬁdence interval (95% CI 1.2–163.9). Interestingly, a fam-
ily history of stomach cancer was associated with a nearly 2-
fold relative risk of gallbladder cancer [12].
Analysisofthe>10-million-person-largeSwedishCancer
Registry revealed a 5.2-fold increased risk of gallbladder can-
cer in the oﬀspring of patients with gallbladder cancer [65].
There was a similar (3.8-fold), but only borderline signif-
icant, risk of extrahepatic bile-duct cancer when a family
history of maternal ovarian cancer was present [65].
Several studies have reported an association between a
familyhistoryofgallstonesandgallbladdercancer.Inarecent
study from China’s Shanghai Cancer Institute, Hsing et al.
[85]c o n ﬁ r m e de a r l i e rr e p o r t s[ 86] that simply a family his-
tory of gallstones conferred an increased risk of gallbladder
cancer (2.1-fold [85]t o3 . 6 - f o l d[ 86]), even after adjustment
for age, gender, marital status, education, smoking, alcohol
drinking body mass index, and importantly, the presence of
gallstones, which themselves further increase the risk.
3.2.1. Speciﬁc Diseases with Inherited Predisposition for Bile-
Duct Cancer. In a cohort of 472 patients from 15 diﬀerent
families with HNPCC, cancer of the biliopancreatic tract was
seen in 18 patients, 11 (79%) of which were conﬁrmed as
arising in the biliary tree or ampulla of Vater [87]. Despite
a >9-fold increased risk of bile-duct cancer in patients with
HNPCC [88], routine screening for bile-duct cancer has not
been recommended [89], owing in large part to the diﬃculty
in detecting these cancers and their rarity.
Muir-Torre syndrome (MTS) is an autosomal dominant
syndrome described in the 1960s [90, 91] that predisposes
to sebaceous skin lesions or keratoacanthomas and visceral
tumors. MTS is a variant of HNPCC with the majority
of germ-line mutations occurring in the MSH2 gene [92].
Several cases of bile-duct and ampullary cancers have been
reportedinassociationwithMTS[93–95],includingareport
of a novel missense mutation in the MSH2 gene [93]. Al-
thoughscreeningforbiliarycancersisnotcurrentlypractical,
it has been suggested that screening for ampullary cancers in
MTS patients would have a favorable risk/beneﬁt ratio [95].International Journal of Surgical Oncology 7
Bilesaltexportpumpdeﬁciency(BSEP),causedbymuta-
tions in ABCB11 [96], has been associated with bile-duct
cancer [97]. In a study of 82 diﬀerent ABCB11 mutations
in 109 families [74], 19 of 128 patients (15%) with BSEP
mutations developed hepatobiliary mutations, but only 2 of
the 19 were bile-duct cancers, the remaining being HCC.
4. Summary
Among all hereditary cancers of the pancreas, liver, and
biliary tree, only those of the pancreas have been studied well
enough to allow for recommendations regarding screening
and surveillance. While several known but rare forms of her-
editary hepatobiliary cancer exist, screening recommenda-
tion cannot be made at this time due to the scarcity of
available data. In contrast, any individual with a risk of PC
estimated to be ≥10-fold should be screened with EUS by
an experienced endoscopist in an experienced center after
genetic counseling and informed consent, provided that the
individual is willing to undergo pancreatectomy. Screening
should begin at least 10 years prior to the age of the youngest
aﬀected relative and perhaps even earlier for select patients,
such as smokers.
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